Now Enrolling! Aegle's Phase 1/2a clinical trial of AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. To learn more about the Aegle DEB Clinical Study, please see our Informational Brochure or visit ClinicalTrials.gov. Informational Brochure: https://lnkd.in/eUJjyVGW
Aegle Therapeutics’ Post
More Relevant Posts
-
New Clinical Trial for RDEB! 👇👇 Learn more at https://bit.ly/3QgpsBg or via the links below.
Now Enrolling! Aegle's Phase 1/2a clinical trial of AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. To learn more about the Aegle DEB Clinical Study, please see our Informational Brochure or visit ClinicalTrials.gov. Informational Brochure: https://lnkd.in/eUJjyVGW
Aegle DEB Clinical Study Informational Brochure
cdn.aegletherapeutics.com
-
Check out this article on GP-2250 and our #pancreaticcancer clinical trial by Dr. Anup Kasi from University of Kansas Medical Center: https://lnkd.in/etX9hHkp.
Potential Therapy Takes a Two-Prong Attack on Pancreatic Cancer
https://letswinpc.org
-
Exploring the World of Clinical Research: Worldwide Clinical Trials vs Vial 🔍 Selecting the right Contract Research Organization (CRO) is pivotal in the realm of clinical trials. In our latest article, we compare Vial and Worldwide Clinical Trials, shedding light on their distinctive approaches and what sets each CRO apart. Read the full article here: https://lnkd.in/evygDxBC
Worldwide Clinical Trials vs Vial | Pros and Cons - Vial
https://vial.com
-
The TidalHealth Richard A. Henson Research Institute is overjoyed to share with you the successes of one of their clinical trials, AZALEA-TIMI 71. AZALEA is a phase 2 trial intended to evaluate the safety and tolerability of Abelacimab, a novel anticoagulant, compared with rivaroxaban in patients with atrial fibrillation who are at risk of having a stroke. Learn more: https://lnkd.in/d8EP6cvJ
Abelacimab: The New Anticoagulant on the Block
tidalhealth.org
-
#Clinicaltrial matching is critical for enrolling the right patients in #precisiononcology studies. Discover ways to enhance the process: https://bit.ly/3LpidEQ #PrecisionOncology #ClinicalResearch
The Multi-Faceted World of Clinical Trial Matching in Precision Oncology Studies | Premier Research
https://premier-research.com
-
'Current clinical trials are designed using a drug-centric model. An N-of-1 trial is a departure from this, as it proposes a patient-centric model. In this regard, a patient-centered N-of-1 trial with a modified design standardized to assess different dosages in the same patient (instead of the regular sequential N-of-1 design) may lead to enhanced and swift development of novel agents. As such, patients act as their own control, effectively eliminating any possible interpatient heterogeneity bias.' https://lnkd.in/dfRGrPyV
N-of-1 Trials in Cancer Drug Development
aacrjournals.org
-
From fears of being treated like a guinea pig to simply not having enough time or money, people have many reasons why they don't enroll in a clinical trial (... if they even know what one is). Here, Adrelia Allen, executive director, clinical trial patient diversity, at Merck, outlines three top reasons people don't participate in trials and offers ways to overcome them. #clinicaltrials #clinicalresearch
3 Reasons People Don't Enroll In Clinical Trials — And How To Overcome Them
clinicalleader.com
CEO, Managing Director, Entrepreneur
1moIt is a wonderful opportunity to work side by side with an organization as amazing as debra of America!